Valuation: Zai Lab Limited

Market Cap 2.08B 1.8B 1.68B 1.55B 2.92B 198B 2.95B 19.83B 7.75B 98.78B 7.8B 7.63B 327B P/E 2026 *
-8.24x
P/E 2027 * -9.84x
Enterprise Value 1.58B 1.38B 1.28B 1.18B 2.23B 151B 2.25B 15.12B 5.91B 75.32B 5.95B 5.82B 250B EV / Sales 2026 *
3.54x
EV / Sales 2027 * 2.87x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.23%
1 week-0.63%
Current month+0.64%
1 month-3.09%
3 months-9.77%
6 months+9.03%
Current year+7.53%
1 week 15.3
Extreme 15.3
16.3
1 month 15.3
Extreme 15.3
17.8
Current year 13.2
Extreme 13.2
21
1 year 13.2
Extreme 13.2
33.4
3 years 12.4
Extreme 12.4
38.2
5 years 12.4
Extreme 12.4
130
10 years 12.4
Extreme 12.4
162
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%-0.63% - - 2.08B
+0.19%+9.42%+33.09%-0.75% 75.96B
+3.22%-8.05%+23.47%+188.66% 49.03B
+3.72%-4.71%-8.40%+20.60% 47.88B
+1.42%+2.02%-51.10%-50.16% 43.39B
+3.29%+1.38%+57.68%-22.49% 30.8B
+1.83%-7.18%+54.54%+89.53% 24.45B
+3.36%+2.12%+106.19%-47.32% 22.75B
+4.15%+0.67%-8.56%+210.84% 19.24B
+1.35%-6.55%+60.80%+118.48% 15.87B
Average +1.65%-0.84%+29.74%+56.38% 36.6B
Weighted average by Cap. +1.87%+0.79%+22.38%+43.60%

Financials

2026 *2027 *
Net sales 448M 389M 362M 333M 630M 42.58B 637M 4.27B 1.67B 21.29B 1.68B 1.64B 70.53B 595M 516M 481M 442M 836M 56.56B 846M 5.68B 2.22B 28.27B 2.23B 2.18B 93.68B
Net income -244M -212M -198M -182M -343M -23.22B -347M -2.33B -911M -11.61B -917M -897M -38.47B -159M -138M -129M -118M -223M -15.11B -226M -1.52B -593M -7.55B -597M -583M -25.03B
Net Debt -493M -428M -400M -367M -694M -46.94B -702M -4.71B -1.84B -23.47B -1.85B -1.81B -77.75B -371M -322M -301M -276M -522M -35.33B -528M -3.54B -1.39B -17.66B -1.39B -1.36B -58.51B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change
05/08/26 EUR 15.70 -3.68%
04/08/26 EUR 16.30 +4.49%
03/08/26 EUR 15.60 0.00%
31/07/26 EUR 15.60 +1.96%
30/07/26 EUR 15.30 -3.16%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.49USD
Average target price
33.30USD
Spread / Average Target
+80.12%

Quarterly revenue - Rate of surprise